Skip to main content
Cardiovascular Diabetology logoLink to Cardiovascular Diabetology
. 2018 Mar 9;17:38. doi: 10.1186/s12933-018-0676-1

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Honghong Zou 1,#, Baoqin Zhou 1,#, Gaosi Xu 1,
PMCID: PMC5844178  PMID: 29523130

Correction to: Cardiovasc Diabetol (2017) 16:65 10.1186/s12933-017-0547-1

Following publication of the original article [1] the authors reported that the first affiliation (“Medical Center of the Graduate School, Nanchang University, China”) had been added in error, and that the correct author information is as given in this erratum.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Footnotes

Honghong Zou and Baoqin Zhou contributed equally to this work

The original article can be found online at https://doi.org/10.1186/s12933-017-0547-1.

Reference

  • 1.Zou H, Zhou B, Gaosi X. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017;16:65. doi: 10.1186/s12933-017-0547-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cardiovascular Diabetology are provided here courtesy of BMC

RESOURCES